Professor Pierluigi Bove explains why, when blood appears in the urine and a cystoscopy may be needed, postponing a check-up can end up costing more than the disease itself.
When blood appears in the urine, many people avoid getting checked right away: fear sets in—of an unfavorable diagnosis, of cystoscopy, even of the word “cancer.” But postponing a check-up is often the choice that costs the patient the most.
There are symptoms that scare because they are painful, and symptoms that scare because they immediately make you think of something serious. Blood in the urine almost always falls into the second category: it appears suddenly, creates alarm, and often triggers a simple psychological response. You hope it will go away. You try to forget it. You postpone.
The point is that, when it comes to the bladder, lost time is rarely neutral. From that moment on, for many people, the problem is no longer just the symptom. A concrete doubt remains: understanding what it depends on and whether it should be investigated further. Postponing the check-up can mean living for a long time with uncertainty and concern, and above all risking arriving later to an assessment that, if done promptly, would have clarified the situation.
Blood in the urine is not “just a nuisance”
Many patients describe the same pattern: an episode of hematuria, perhaps without pain, and the tendency to give it a reassuring explanation. It may be attributed to cystitis, a stressful period, or poor hydration. Sometimes an antibiotic is taken without a clear clinical assessment and, if the symptom lessens, it can feel as if the problem has been solved.
Professor Pierluigi Bove, Head of the U.O.S.D. of Robotic and Minimally Invasive Urology (URMI) at Policlinico Tor Vergata and Associate Professor of Urology at the University of Rome Tor Vergata, often sums it up with a sentence that is very useful in clinic: “Blood in the urine isn’t something you interpret: you evaluate it in context. And you do it right away.”
This is not alarmism. It is clinical order: understanding the origin of the symptom, ruling out more serious causes, and only afterward providing reassurance when appropriate.
Cystoscopy: often feared, but not always the first step
One of the main reasons for delayed diagnosis is fear of cystoscopy. But one point should be made clear: cystoscopy is not automatically the first test for every episode of hematuria. The first step, as always, is to evaluate the patient properly.
“Before thinking about tests, you need to understand who’s in front of you. The medical history already guides a great deal,” Professor Bove explains.
In particular, in some older patients or in those taking antiplatelet or anticoagulant medications, hematuria may have causes that can already be understood through clinical assessment. In other cases, there may be symptoms consistent with bladder inflammation. For this reason, in practice, evaluation often proceeds step by step, starting with less invasive tools.
An ultrasound, for example, can already rule out more obvious issues and provide useful information about the bladder, kidneys, and urinary tract. If the picture remains unclear, if hematuria persists, or if there are elements that require a targeted assessment, then cystoscopy becomes an important step.
“When it is needed, cystoscopy is the test that allows us to look directly inside the bladder,” Professor Bove specifies. “But you get there with judgment, after a proper assessment and after the first investigations.”
Put simply: it is not about “jumping” straight to a test, but about not postponing the evaluation. And when further investigation is indicated, doing it at the right time prevents prolonged uncertainty and delayed decisions.
Why arriving late changes the rules
In bladder cancer, the difference is not only between “having” or “not having” a disease. Often, the real difference is between identifying a more superficial and manageable form and, instead, facing a more advanced situation.
Clinically, we often speak about non–muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). These are acronyms, but the reality behind them is simple: when the disease remains superficial, the approach can be more conservative and management more controllable; when it becomes muscle-invasive, the pathway tends to be more demanding, with a need for more aggressive treatments and a stronger impact on the patient’s life.
“It’s not just a diagnosis: it’s the type of diagnosis that makes the difference,” Professor Bove notes. “And that difference is often decided by time.”
A monitored bladder is a more protected bladder
Here the paradox comes into play: fear of having the bladder checked is exactly what increases the likelihood of having to face more difficult choices. And this is true even when the outcome is not oncological: ruling out a serious cause is not wasted time, but reassurance based on a medical finding.
In many cases, a timely check-up makes it possible to set a reasoned plan: without alarmism, without burdening the situation with unnecessary worries, and above all with fewer repeated tests due to the lack of a clear picture. You move from uncertainty to defining the problem. And in medicine, clarity is already a concrete benefit.
After the patient, there is also a broader issue
There is another aspect that becomes clear when looking at the wider picture: bladder cancer is among the most resource-intensive to manage over time for healthcare systems, because it requires long-term follow-up, repeated checks, and because the risk of recurrence demands strict surveillance.
But this does not mean “doing tests at random.” It means doing them better. Today the key concept is appropriateness: risk stratification, choosing timing and tools coherently, and—when indicated—also evaluating the role of certain urine tests as support in monitoring, without replacing what must be done and without falling into automatic routines.
“The point is not to increase the number of checks,” Professor Bove specifies. “The point is to choose intelligent follow-up, built around the patient’s profile.”
And in the end, it always comes back to the same idea: the goal is not to chase the disease, but to anticipate it when possible.
“In bladder cancer, it’s not early diagnosis that costs too much. It’s the fear of getting evaluated,” Professor Bove concludes.
References:
bladder cancer, blood in urine hematuria, hematuria when to worry, early diagnosis bladder, outpatient cystoscopy, fear of cystoscopy, delayed diagnosis hematuria, urologic oncology, bladder cancer NMIBC, bladder cancer MIBC, bladder cancer follow-up, bladder cancer recurrence, bladder cancer surveillance, bladder cancer risk stratification, urine tests bladder cancer, appropriateness of urology follow-up, patient quality of life, doctor–patient communication, Prof. Pierluigi Bove, URMI Robotic and Minimally Invasive Urology, Policlinico Tor Vergata, urologic oncologist Rome
